[Use of verapamil for treating patients with unstable stenocardia].
Verapamil in a 400 mg daily dose was used in 64 coronary patients with the unstable angina syndrome, their condition being assessed by means of coronarography (40) and the cold test (24). Anginal attacks subsided in more than 60% of the patients treated with verapamil alone or in combination with long-acting nitrates, and their treatment was continued on an out-patient basis. In 24 patients, the drug had no effect and was discontinued. Typically, all the three major coronary arteries were affected in these patients, and they were refractory to other antianginal drugs. Myocardial infarction developed during hospital stay in 7 (11%) patients. The cold test has no predictive value with respect to the efficiency of verapamil in these patients, as the rate of positive tests is rather low. The drug taken in a 400 mg dose is easily tolerated by patients over long periods of treatment (up to 1.5 pears), however, their circulatory status should be closely monitored because of a risk of heart failure and arterial hypotension.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000627:therapeutic use; D013997:Time Factors; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D009566:Nitrates; D014700:Verapamil
Primenenie verapamila dlia lecheniia bol'nykh s nestabil'noĭ stenokardieĭ.